TWI821235B - 以ccr6或cxcr2之拮抗劑治療廣泛性膿疱型乾癬之方法 - Google Patents

以ccr6或cxcr2之拮抗劑治療廣泛性膿疱型乾癬之方法 Download PDF

Info

Publication number
TWI821235B
TWI821235B TW108100708A TW108100708A TWI821235B TW I821235 B TWI821235 B TW I821235B TW 108100708 A TW108100708 A TW 108100708A TW 108100708 A TW108100708 A TW 108100708A TW I821235 B TWI821235 B TW I821235B
Authority
TW
Taiwan
Prior art keywords
antagonist
ccr6
cxcr2
compound
cells
Prior art date
Application number
TW108100708A
Other languages
English (en)
Chinese (zh)
Other versions
TW201936600A (zh
Inventor
詹姆士 J 坎貝爾
凱倫 埃布斯沃思
安東尼 克瑞辛斯基
帆克 羅迪 馬利
傑夫瑞 馬克馬宏
羅瑾德 斯穎
楊菊
喻超
朋烈 張
Original Assignee
美商卡默森屈有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商卡默森屈有限公司 filed Critical 美商卡默森屈有限公司
Publication of TW201936600A publication Critical patent/TW201936600A/zh
Application granted granted Critical
Publication of TWI821235B publication Critical patent/TWI821235B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW108100708A 2018-01-08 2019-01-08 以ccr6或cxcr2之拮抗劑治療廣泛性膿疱型乾癬之方法 TWI821235B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862614927P 2018-01-08 2018-01-08
US62/614,927 2018-01-08
US201862715503P 2018-08-07 2018-08-07
US62/715,503 2018-08-07

Publications (2)

Publication Number Publication Date
TW201936600A TW201936600A (zh) 2019-09-16
TWI821235B true TWI821235B (zh) 2023-11-11

Family

ID=67140280

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108100708A TWI821235B (zh) 2018-01-08 2019-01-08 以ccr6或cxcr2之拮抗劑治療廣泛性膿疱型乾癬之方法

Country Status (10)

Country Link
US (2) US11207294B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737366B1 (cg-RX-API-DMAC7.html)
JP (1) JP7322036B2 (cg-RX-API-DMAC7.html)
CN (1) CN111867579B (cg-RX-API-DMAC7.html)
AU (1) AU2019205786B2 (cg-RX-API-DMAC7.html)
ES (1) ES3067325T3 (cg-RX-API-DMAC7.html)
IL (1) IL275839B2 (cg-RX-API-DMAC7.html)
MA (1) MA50424A (cg-RX-API-DMAC7.html)
TW (1) TWI821235B (cg-RX-API-DMAC7.html)
WO (1) WO2019136370A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
ES3067325T3 (en) 2018-01-08 2026-05-21 Chemocentryx Inc Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
CN117018202A (zh) * 2019-07-08 2023-11-10 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
TWI904157B (zh) 2020-04-30 2025-11-11 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
JP2024539987A (ja) 2021-10-26 2024-10-31 イドルシア・ファーマシューティカルズ・リミテッド Ccr6受容体調節剤
ES3073199T3 (en) 2021-10-28 2026-07-09 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087610A1 (en) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Inhibitors of cxcr2
WO2017087607A1 (en) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulators of chemokine receptors

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AR033803A1 (es) 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
WO2001092202A1 (en) 2000-05-30 2001-12-06 Smithkline Beecham Corporation Il-8 receptor antagonists
DE60230722D1 (de) 2001-01-16 2009-02-26 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
EP1355875A1 (en) 2001-02-02 2003-10-29 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR20100008794A (ko) 2001-04-16 2010-01-26 쉐링 코포레이션 Cxc-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
NZ535314A (en) 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
DE602004025458D1 (de) 2003-04-18 2010-03-25 Schering Corp SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID
CN1914187B (zh) 2004-01-30 2012-01-25 先灵公司 Cxc趋化因子受体配位体的结晶多晶型物
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
JP2009542700A (ja) 2006-07-07 2009-12-03 シェーリング コーポレイション Cxcケモカイン受容体リガンドとしての3,4−ジ置換シクロブテン−1,2−ジオン
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
MX2009013276A (es) 2007-06-06 2010-01-25 Novartis Ag Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
EP2178826B1 (en) 2007-07-03 2017-05-17 Merck Sharp & Dohme Corp. Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
US20100249439A1 (en) 2007-07-05 2010-09-30 Vincenzo Liotta Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
MX2010014310A (es) 2008-06-24 2011-02-15 Topotarget As Derivados de acido escuarico como inhibidores de la nicotinamida.
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2350067A2 (en) 2008-10-16 2011-08-03 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
WO2013030803A1 (en) 2011-09-02 2013-03-07 Novartis Ag Choline salt of an anti - inflammatory substituted cyclobutenedione compound
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
SI2780373T1 (sl) * 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
WO2015170430A1 (ja) 2014-05-08 2015-11-12 学校法人慶應義塾 大動脈解離後の炎症性障害抑制剤
EP3220951A1 (en) 2014-11-17 2017-09-27 MedImmune Limited Therapeutic combinations and methods for treating neoplasia
ES3067325T3 (en) 2018-01-08 2026-05-21 Chemocentryx Inc Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087610A1 (en) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Inhibitors of cxcr2
WO2017087607A1 (en) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulators of chemokine receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Wu et al., "Tonsillectomy as a Treatment for Psoriasis: A Review", Journal of Dermatological Treatment, 25(6), 2014, pp 482-486. *

Also Published As

Publication number Publication date
US11684606B2 (en) 2023-06-27
US20190209527A1 (en) 2019-07-11
AU2019205786A1 (en) 2020-08-06
CA3087701A1 (en) 2019-07-11
EP3737366A2 (en) 2020-11-18
US11207294B2 (en) 2021-12-28
JP7322036B2 (ja) 2023-08-07
WO2019136370A3 (en) 2020-04-16
US20220280481A1 (en) 2022-09-08
ES3067325T3 (en) 2026-05-21
WO2019136370A2 (en) 2019-07-11
CN111867579B (zh) 2023-11-24
MA50424A (fr) 2020-08-26
CN111867579A (zh) 2020-10-30
IL275839B2 (en) 2024-02-01
JP2021510160A (ja) 2021-04-15
IL275839B1 (en) 2023-10-01
TW201936600A (zh) 2019-09-16
IL275839A (en) 2020-08-31
EP3737366A4 (en) 2022-07-27
AU2019205786B2 (en) 2023-12-14
EP3737366B1 (en) 2026-02-25
EP3737366C0 (en) 2026-02-25

Similar Documents

Publication Publication Date Title
US11684606B2 (en) Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
JP7611189B2 (ja) Pd-1阻害剤又はpd-l1阻害剤と組み合わせてccr1アンタゴニストを投与することによる腫瘍負荷の低減
JP7788814B2 (ja) C3腎症を処置する方法
EP2167038B1 (en) Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
US20220213115A1 (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
WO2022143628A1 (zh) 预防或治疗抗肿瘤剂相关疾病或病症的方法
JP2024178420A (ja) 多発性硬化症を治療するためのlou064
US20220072003A1 (en) Organic compounds
US20250186446A1 (en) Organic compounds
CN105813637A (zh) 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
CN113453759A (zh) 治疗巨细胞动脉炎
CA3087701C (en) Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
JPWO2020004404A1 (ja) IL−1β阻害薬
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
Ward et al. Antibodies in Phase III Studies for Immunological Disorders
NZ765534B2 (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
HK40004572B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors